Lannett Company Inc


Lannett Company, Inc.

Lannett Company, Inc. founded in 1942, develops, manufactures and distributes generic prescription pharmaceutical products in tablet, capsule and oral liquid forms to customers throughout the United States. Lannett markets its products primarily to drug wholesalers, retail drug chains, distributors, and government agencies.

We employ a staff of dedicated people who work together to produce drug products that sick people can afford to buy that will treat their illness, make them well, reduce suffering and improve the quality of their lives.

News & Events

11/17/14 Lannett Announces Ernest J. Sabo, the company’s vice president of regulatory affairs and chief compliance officer, will retire.

Lannett Company, Inc. (NYSE: LCI) today announced that Ernest J. Sabo, the company’s vice president of regulatory affairs and chief compliance officer, will retire from the company, effective January 2, 2015. Read More

11/03/14 Lannett Reports Net Sales of $93 Million, EPS of $0.94 For Fiscal 2015 First Quarter -- Company Raises Outlook for Fiscal 2015--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 first quarter ended September 30, 2014. For the fiscal 2015 first quarter, net sales doubled to $93.4 million from $45.8 million in last year’s first quarter. Read More
Listen To Audio Webcast

11/03/14 Lannett Announces Positive FDA Inspection Results

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has completed its cGMP compliance inspection of Lannett's wholly owned subsidiary Cody Laboratories, Inc. (Cody), a manufacturer of active pharmaceutical ingredients (APIs) and finished dosage form products. Read More

10/29/14 LANNETT RECEIVES FDA APPROVAL FOR LETROZOLE TABLETS USP 2.5 MG

Lannett Company, Inc. (NYSE: LCI) today today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Letrozole Tablets USP, 2.5 mg, the therapeutic equivalent to the reference listed drug, Femara Tablets, 2.5 mg, of Novartis Pharmaceuticals Corporation. Read More

10/29/14 LANNETT TO PRESENT AT THE 2014 CREDIT-SUISSE HEALTHCARE CONFERENCE ON NOV 11

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Credit-Suisse 2014 Healthcare Conference on Tuesday, November 11, 2014, at 4:30 p.m. Mountain Standard Time (6:30 p.m. Eastern Standard Time) at The Biltmore Hotel in Phoenix, AZ. Read More
Listen To Audio Webcast

10/23/14 Lannett Announces Preliminary Fiscal 2015 First Quarter Net Sales Of Approximately $93 Million, EPS Between $0.91 And $0.94 -Company to Report Full Financial Results, Host Conference Call on November 3-

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2015 first quarter net sales of approximately $93 million and diluted earnings per share between $0.91 and $0.94. Read More
Listen To Audio Webcast

Authorized Distributors of Record

Lannett Company Inc is the Authorized Distributors of Record for many products.
Download the full list.

Community Relations

Our dedicated employees strive to position Lannett as an industry leader that is focused on quality and integrity, as well as giving back to the community we serve. Lannett has a history of supporting schools, hospitals, veterans and their families, institutions, rehabilitation centers, cancer research, as well as the local fire and police departments. Read More.

Wholesale distributors that display the VAWD Seal as part of their accreditation have undergone a criteria compliance review, including a rigorous review of their operating policies and procedures, licensure verification, survey of facility and operations, background checks, and screening through the NABP Clearinghouse. Accredited facilities are reviewed annually and undergo a site survey every three years.


Made in USA

Made in America